Impact of Reducing Antihypertensive Treatment on Mortality in Frail Subjects With Low Systolic Blood Pressure (SBP).

Lab values

• Patients in whom no antihypertensive molecule can be reduced for specific reasons (heart failure with ejection fraction \<40%, fluid retention due to heart failure, coronary artery disease and diabetic nephropathy).

Other

• Patients with an estimated life expectancy of \<3 months
• Patients who have already been included in this study or in another study at the same time

• Male and female patients aged 80 and over
• Patients living in nursing homes
• Patients with a SBP \< 130 mmHg measured in Medical-Social Institutions using the connected blood pressure monitor supplied for the study (average of the last 2 out of 3 measurements after 10 min rest)
• Hypertensive patients whose treatment contains at least 2 antihypertensive molecules and whose treatment has been stabilised for at least :
  • 3 weeks in the case of the introduction or discontinuation of an anti-HBP drug
  • 2 weeks in the case of a change in the dosage of one of the anti-HBP drugs.
• Patients affiliated to a social security scheme
• Patients who have signed the informed consent form (failing which, the legal representative)
• Patients with dementia or with a severe reduction in physical function (impaired vision, asthenia, advanced osteoarthritis, severe tremors, etc.) and/or cognitive function may be included in this study with the agreement of their carers or family/relatives.